European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 256-262 , March 2008

Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?

  • M.E. Schwartz

      Affiliations

    • Recanati–Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • F. D'Amico

      Affiliations

    • Unità di Chirurgia Epatobiliare e Trapianto Epatico, Università di Padova, Italy
    • ,
  • A. Vitale

      Affiliations

    • Chirurgia Oncologica, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy
    • ,
  • S. Emre

      Affiliations

    • Recanati–Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA
    • ,
  • U. Cillo

      Affiliations

    • Unità di Chirurgia Epatobiliare e Trapianto Epatico, Università di Padova, Italy

,Accepted 20 July 2007.

References 

  1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817
  2. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372
  3. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona – 2000 EASL conference. J Hepatol. 2001;35:421–430
  4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524
  5. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609–1619
  6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907
  7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208
  8. Iwatsuki S, Gordon RD, Shaw BW, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg. 1985;202:401–407
  9. O'Grady JG, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease: results in 93 consecutive patients. Ann Surg. 1988;207:373–379
  10. Olthoff KM, Millis JM, Rosove MH, et al. Is liver transplantation justified for the treatment of hepatic malignancies?. Arch Surg. 1990;125:1261–1268
  11. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145–151
  12. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  13. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–1577
  14. UNOS/OPTN policy 3.6.4.4. Available at: <http://www.optn.org>[accessed 15.01.05]
  15. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150–159
  16. Yao FY, Ferrel L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403
  17. Kaihara S, Kiuchi T, Ueda M, et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation. 2003;75:S37–S40
  18. Sotiropoulos GC, Malagò M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?. Transplantation. 2005;79:483–487
  19. Shah SA, Tan JCC, McGilvray ID, et al. Accuracy of staging as a predictor of recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633–1639
  20. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086–1092
  21. Kirimlioglu H, Dvorchick I, Ruppert K, et al. Hepatocellular carcinomas in native livers from patients with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology. 2001;34:502–510
  22. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086
  23. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708–2716
  24. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of the tumor characteristics on outcome. Ann Surg. 1998;228:479–490
  25. Molmenti E, Klintmalm G. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl. 2002;8:736–748
  26. Herrero JL, Sangro B, Quiroga J, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001;7:631–636
  27. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235:533–539
  28. Salizzoni M, Zamboni F, Lupo F, et al. Liver transplantation for early-detected, multifocal hepatocellular carcinoma. Br J Surg. 2001;88:1194–1195
  29. Goodman J, Glasgow SC, Schnitzler M, et al. Liver transplantation for hepatocellular carcinoma. Expanding special priority to include stage III disease. Arch Surg. 2005;140:459–464
  30. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology. 1997;26:444–450
  31. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 2000;191:389–394
  32. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?. Cancer. 2000;88:538–543
  33. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl. 2003;9:693–696
  34. Yao FY, Ferrel L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–774
  35. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451–461
  36. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136:25–30
  37. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224–232
  38. Park NH, Chung YH, Youn KH, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001;33:397–401
  39. Lauwers GY, Terris B, Balis KP, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic index. Am J Surg Pathol. 2002;26:25–34
  40. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527–1536
  41. Margarit C, Charco R, Hidalgo E, et al. Liver transplantation for malignant disease: selection and pattern of recurrence. World J Surg. 2002;26:257–263
  42. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652–659
  43. Yamanaka J, Yamanaka N, Nakasho K, et al. Clinicopathologic analysis of stage II–III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastrenterol Hepatol. 2000;15:1192–1198
  44. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440
  45. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873–883
  46. Yao FY, Bass NM, Nikolai B, et al. A follow up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003;9:684–692
  47. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the model of end-stage liver disease (MELD) organ allocation policy. Liver Transpl. 2004;10:621–630
  48. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338
  49. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed.. Chicago, USA: Springer; 2002;p. 131–44
  50. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol. 2004;40:124–131
  51. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723–731
  52. Okuda K, Othtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–928
  53. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751–755
  54. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol. 1999;31:133–141
  55. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, the Cancer of the Liver Italian Program staging system. Cancer. 2002;94:1760–1769
  56. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716
  57. The Cancer of the Liver Italian Program (CLIP) Investigators . Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840–845
  58. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–215
  59. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding esophageal varices. Br J Surg. 1973;60:646–664
  60. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. Philadelphia: Lippincott-Raven; 1997;
  61. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396–1405
  62. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis. A reasonable strategy?. Ann Surg. 2003;238:508–517
  63. Majno PE, Sarasin FP, Mentha G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology. 2000;31:899–906
  64. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 2004;10:1294–1300
  65. Bassanello M, Cillo U, Vitale A, et al. Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. Anticancer Res. 2003;23:4047–4054
  66. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238:885–892[discussion 892–893]
  67. Cillo U, Vitale A, Brolese A, et al. Partial hepatectomy as first line treatment of patients with hepatocellular carcinoma. J Surg Oncol. October 25, 2006;
  68. Morioka D, Tanaka K, Matsuo K, et al. Applicability of the Milan criteria for determining liver transplantation as a first-line treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006;
  69. Sutcliffe R, Maguire D, Prtmann M, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg. 2006;93:11–18
  70. Altimari A, Fiorentino M, Gabusi E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35:332–338
  71. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998;27:1554–1562
  72. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32:78–84
  73. Endo K, Ueda T, Ueyama J, et al. Immunoreactive E-cadherin, α-catenin, β-catenin, γ-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, patients' survival. Hum Pathol. 2000;31:558–565
  74. Fiorentino M, Altimari A, D'Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000;6:3966–3972
  75. Hsu HC, Jeng YM, Mao TL, et al. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B and with favourable prognosis. Am J Pathol. 2000;157:763–770
  76. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8:450–456
  77. Ito Y, Matsuura N, Sakon M, et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer. 1999;81:747–751
  78. Ito Y, Matsuura N, Sakon M, et al. Expression and prognostic roles of the G1–S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999;30:90–99
  79. Kawate S, Fukusato T, Ohwada S, et al. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology. 1999;57:157–163
  80. Kobayashi T, Kubota K, Takayama T, Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001;181:284–288
  81. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000;6:2726–2734
  82. Matsuda Y, Ichida T, Genda T, et al. Loss of p16 contributes to p27 sequestration by cyclin D(1)–cyclin dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2003;9(9):3389–3396
  83. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res. 2001;7:594–599
  84. Nanashima A, Yano H, Yamaguchi H, et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol. 2004;39(2):148–154
  85. Nhieu JTV, Renard CA, Wei Y, et al. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155:703–710
  86. Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001;21:657–662
  87. Ouchi K, Sugawara T, Ono H, et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg. 2000;17:42–48
  88. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002;8:385–392
  89. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–563
  90. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004;10:449–455
  91. Vitale A, Brolese A, Zanus G, et al. Multimodal therapy before liver transplantation for hepatocellular carcinoma. Hepatol Res. January 31, 2005;
  92. Lu DSK, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130–1137
  93. Huo TI, Lin HC, Lee FY, et al. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl. 2004;10:1507–1513
  94. Yamashiki N, Tateishi R, Yoshida H, et al. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for transplantation. Liver Transpl. 2005;11:508–514
  95. Yao FY, Kinkhabwala M, LaBerdge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795–804
  96. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11:1505–1514
  97. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–1267
  98. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127(Suppl. 1):S261–S267
  99. Schwartz M. Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2004;10(2, Suppl. 1):S81–S85
  100. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver disease. Am J Transplant. 2006;6:1416–1421
  101. Ravioli M, Grazi GL, Ercolani G, et al. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation. 2006;81:525–530
  102. Sotiropoulos GC, Paul A, Momenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with “livers that nobody wants”. Transplantation. 2005;80:897–902
  103. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg. 2004;240:451–459
  104. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. Hepatology. 2001;33:1073–1079
  105. Cardillo M, De Fazio N, Pedotti P, et al. Split and whole liver transplantation outcomes: a comparative cohort study. Liver Transpl. 2006;12:402–410
  106. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl. 2003;9:664–671

PII: S0748-7983(07)00520-3

doi: 10.1016/j.ejso.2007.07.208

European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 256-262 , March 2008

Article Tools

* Image Usage & Resolution